Use of Antiemetics in cancer patients: ASCO Guideline Update
American Society of Clinical Oncology (ASCO) has updated it's guidelines on Antiemetics in cancer patients. The guidelines published in the journal of Clinical Oncology blue picture include new anticancer agents, antiemetics, and antiemetic regimens and provide recommendations on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs).
The guidelines will primarily address Medical and radiation oncologists, oncology nurses, nurse practitioners, physician assistants, oncology pharmacists, and patients with cancer.
Recommendations
Adult Patients
High-emetic-risk antineoplastic agents
Adults treated with cisplatin and other high-emetic-risk single agents should be offered a 4-drug combination of an NK1 receptor antagonist, a serotonin (5-HT3) receptor antagonist, dexamethasone, and olanzapine (day 1). Dexamethasone and olanzapine should be continued on days 2 to 4 (Type: evidence based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Adults treated with an anthracycline combined with cyclophosphamide should be offered a 4-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, dexamethasone, and olanzapine (day 1). Olanzapine should be continued on days 2 to 4 (Type: evidence based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Moderate-emetic-risk antineoplastic agents
Adults treated with carboplatin area under the curve (AUC) ≥ 4 mg/mL/min should be offered a 3-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone (day 1) (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Adults treated with moderate-emetic-risk antineoplastic agents (excluding carboplatin AUC ≥ 4 mg/mL/min) should be offered a 2-drug combination of a 5-HT3 receptor antagonist and dexamethasone (day 1) (Type: evidence based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Adults treated with cyclophosphamide, doxorubicin, oxaliplatin, and other moderate-emetic-risk antineoplastic agents known to cause delayed nausea and vomiting may be offered dexamethasone on days 2 to 3 (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: moderate).
Low-emetic-risk antineoplastic agents
Adults treated with low-emetic-risk antineoplastic agents should be offered a single dose of a 5-HT3 receptor antagonist or a single 8-mg dose of dexamethasone before antineoplastic treatment (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: moderate).
Minimal-emetic-risk antineoplastic agents
Adults treated with minimal-emetic-risk antineoplastic agents should not be offered routine antiemetic prophylaxis (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: moderate).
Antineoplastic combinations
Adults treated with antineoplastic combinations should be offered antiemetics appropriate for the component antineoplastic agent of greatest emetic risk (Type: informal consensus, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).
Adjunctive drugs
Lorazepam is a useful adjunct to antiemetic drugs but is not recommended as a single-agent antiemetic (Type: informal consensus; benefits outweigh harms; Evidence quality: low; Strength of recommendation: moderate).
Cannabinoids
Evidence remains insufficient for a recommendation regarding medical marijuana for the prevention of nausea and vomiting in patients with cancer receiving chemotherapy or radiation therapy. Evidence is also insufficient for a recommendation regarding the use of medical marijuana in place of the tested and US Food and Drug Administration–approved cannabinoids dronabinol and nabilone for the treatment of nausea and vomiting caused by chemotherapy or radiation therapy.
Complementary and alternative therapies
Evidence remains insufficient for a recommendation for or against the use of ginger, acupuncture/acupressure, and other complementary or alternative therapies for the prevention of nausea and vomiting in patients with cancer.
High-dose chemotherapy with stem-cell or bone marrow transplantation
Adults treated with high-dose chemotherapy and stem-cell or bone marrow transplantation should be offered a 3-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone (Type: evidence based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
(New) A 4-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, dexamethasone, and olanzapine may be offered to adults treated with high-dose chemotherapy and stem-cell or bone marrow transplantation. (Type: evidence based, benefits outweigh harms; Evidence quality: low; Strength of recommendation: weak).
Multiday antineoplastic therapy
Adults treated with multiday antineoplastic agents should be offered antiemetics before treatment that are appropriate for the emetic risk of the antineoplastic agent given on each day of the antineoplastic treatment and for 2 days after completion of the antineoplastic regimen (Type: evidence based, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).
Adults treated with 4- or 5-day cisplatin regimens should be offered a 3-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone (Type: evidence based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Breakthrough nausea and vomiting
For patients with breakthrough nausea or vomiting, clinicians should re-evaluate emetic risk, disease status, concurrent illnesses, and medications; and ascertain that the best regimen is being administered for the emetic risk (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: moderate).
Adults who experience nausea or vomiting despite optimal prophylaxis and who did not receive olanzapine prophylactically should be offered olanzapine in addition to continuing the standard antiemetic regimen (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).
Adults who experience nausea or vomiting despite optimal prophylaxis and who have already received olanzapine may be offered a drug of a different class (eg, an NK1 receptor antagonist, lorazepam or alprazolam, a dopamine receptor antagonist, dronabinol, or nabilone) in addition to continuing the standard antiemetic regimen (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate for dronabinol and nabilone, low otherwise; Strength of recommendation: moderate).
Anticipatory nausea and vomiting
All patients should receive the most active antiemetic regimen appropriate for the antineoplastic agents being administered. Clinicians should use such regimens with initial antineoplastic treatment rather than assessing the patient's emetic response with less-effective antiemetic treatment. If a patient experiences anticipatory emesis, clinicians may offer behavioral therapy with systematic desensitization (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: moderate).
High-emetic-risk radiation therapy
Adults treated with high-emetic-risk radiation therapy should be offered a 2-drug combination of a 5-HT3 receptor antagonist and dexamethasone before each fraction and on the day after each fraction, if radiation therapy is not planned for that day (Type: evidence based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Moderate-emetic-risk radiation therapy
Adults treated with moderate-emetic-risk radiation therapy should be offered a 5-HT3 receptor antagonist before each fraction, with or without dexamethasone, before the first 5 fractions (Type: evidence based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: moderate).
Low-emetic-risk radiation therapy
Adults treated with radiation therapy to the brain should be offered breakthrough dexamethasone therapy. Patients who are treated with radiation therapy to the head and neck, thorax, or pelvis should be offered breakthrough therapy with a 5-HT3 receptor antagonist, dexamethasone, or a dopamine-receptor antagonist (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: weak).
Minimal-emetic-risk radiation therapy
Adults treated with minimal-emetic-risk radiation therapy should be offered breakthrough therapy with a 5-HT3 receptor antagonist, dexamethasone, or a dopamine-receptor antagonist (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: weak).
Concurrent radiation and antineoplastic agent therapy
Adults treated with concurrent radiation and antineoplastic agents should receive antiemetic therapy appropriate for the emetic risk level of the antineoplastic agents, unless the risk level of the radiation therapy is higher. During periods when prophylactic antiemetic therapy for the antineoplastic agents has ended and ongoing radiation therapy would normally be managed with its own prophylactic therapy, patients should receive prophylactic therapy appropriate for the emetic risk of the radiation therapy until the next period of antineoplastic therapy, rather than receiving breakthrough therapy for the antineoplastic agents as needed (Type: informal consensus, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).
Pediatric Patients
High-emetic-risk antineoplastic agents
(Updated) Pediatric patients treated with high-emetic-risk antineoplastic agents should be offered a 3-drug combination of a 5-HT3 receptor antagonist, dexamethasone, and aprepitant or fosaprepitant (Type: evidence based, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).
(Updated) Pediatric patients treated with high-emetic-risk antineoplastic agents who are unable to receive aprepitant or fosaprepitant should be offered a 2-drug combination of a 5-HT3 receptor antagonist and dexamethasone (Type evidence based, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).
(Updated) Pediatric patients treated with high-emetic-risk antineoplastic agents who are unable to receive dexamethasone should be offered a 2-drug combination of palonosetron and aprepitant or fosaprepitant (Type: evidence based, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).
Moderate-emetic-risk antineoplastic agents
Pediatric patients treated with moderate-emetic-risk antineoplastic agents should be offered a 2-drug combination of a 5-HT3 receptor antagonist and dexamethasone (Type: evidence based, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).
(Updated) Pediatric patients treated with moderate-emetic-risk antineoplastic agents who are unable to receive dexamethasone should be offered a 2-drug combination of a 5-HT3 receptor antagonist and aprepitant or fosaprepitant (Type: evidence based, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: weak).
Low-emetic-risk antineoplastic agents
Pediatric patients treated with low-emetic-risk antineoplastic agents should be offered ondansetron or granisetron (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: strong).
Minimal-emetic-risk antineoplastic agents
Pediatric patients treated with minimal-emetic-risk antineoplastic agents should not be offered routine antiemetic prophylaxis (Type: informal consensus, benefits outweigh harms; Evidence quality: low; Strength of recommendation: strong).
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should have the opportunity to participate.
For additional information log on to:
www.asco.org/supportive-care-guidelines.
